HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IMC-EB10

directed against FMS-related tyrosine kinase receptor 3 (FLT3) for treatment of leukemia

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        IMC-EB10: 4
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        IMC-EB10: 4
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        IMC-EB10: 4

Experts

1.	Li, Yiwen: 4 articles (02/2010 - 08/2004)
2.	Hicklin, Daniel J: 3 articles (05/2006 - 08/2004)
3.	Piloto, Obdulio: 3 articles (05/2006 - 08/2004)
4.	Small, Donald: 3 articles (05/2006 - 08/2004)
5.	Witte, Larry: 3 articles (05/2006 - 08/2004)
6.	Huso, David: 2 articles (05/2006 - 02/2005)
7.	Balderes, Paul: 2 articles (02/2005 - 08/2004)
8.	Bassi, Rajiv: 2 articles (02/2005 - 08/2004)
9.	Li, Hongli: 2 articles (02/2005 - 08/2004)
10.	Ludwig, Dale L: 2 articles (02/2005 - 08/2004)

Related Diseases

1.	Leukemia 02/15/2010 - "The binding of IMC-EB10 to FLT3 results in antiproliferative effects in vitro and in mouse models engrafted with human leukemia cells that harbor wild-type or constitutively activated FLT3. " 08/15/2004 - "In both EOL-1 xenograft and BaF3-ITD leukemia models, treatment with IMC-EB10 significantly prolongs the survival of leukemia-bearing mice. " 08/15/2004 - "IMC-EB10 treatment inhibits FL-induced phosphorylation of FLT3 in EOL-1 and EM3 leukemia cells and FL-independent constitutive activation of ITD-mutant FLT3 in BaF3-ITD and MV4;11 cells. "
2.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 05/01/2006 - "IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples."
3.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/15/2005 - "When IMC-EB10 was used in vivo to treat nonobese diabetic/severe combined immunodeficient mice given injections of primary FLT3/ITD acute myelogenous leukemia samples or myeloid cell lines with FLT3 expression, it significantly decreased engraftment of leukemic cells and increased survival, respectively. "

Related Drugs and Biologics

1.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Injections